表紙
市場調查報告書

由於Th17細胞的發炎途徑治療藥

Th17 Inflammatory Pathway Therapeutics

出版商 Greystone Research Associates 商品編碼 892533
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
由於Th17細胞的發炎途徑治療藥 Th17 Inflammatory Pathway Therapeutics
出版日期: 2019年07月22日內容資訊: 英文
簡介

免疫介導性發炎性疾病 (IMID) 中,包含第一型糖尿病 (T1D) 、克隆氏症 (CD) 、全身性紅斑性狼瘡 (SLE) 、類風濕性關節炎 (RA) 、全身性硬化症(硬皮症) (SSc) 、多發性硬化症 (MS) 、乾癬等。

由於本報告提供Th17細胞的發炎途徑治療藥調查分析,治療用產品和策略相關的系統性資訊。

摘要整理

Th17細胞的途徑

Th17細胞的發炎途徑連鎖標的

白細胞介素6 (IL-6)

  • 認證核可藥
  • 開發階段的藥

白細胞介素 IL-6R

  • 認證核可藥
  • 開發階段的藥

JAK/TK抑制劑

  • 認證核可藥
  • 開發階段的藥

信號蛋白質

  • STAT

白細胞介素21 (IL-21)

白細胞介素21R (IL-21R)

白細胞介素23 (IL-23)

  • 認證核可藥
  • 開發階段的藥

白細胞介素23R (IL-23R)

白細胞介素17A (IL-17A)

  • 認證核可藥

白細胞介素17C (IL-17C)

  • 開發階段的藥

白細胞介素17A/17F

  • 開發階段的藥

白細胞介素17RA (IL-17RA)

  • 認證核可藥

性狀轉換生長因子β RI/RII (TGF-β RI/RII)

  • 開發階段的藥

維甲酸相關孤兒受體 (RORyt)

  • 開發階段的藥

白細胞介素17

  • 開發階段的藥

白細胞介素22 (IL-22)

市場情形

市場規模

競爭情形

Th17細胞的途徑介導發炎性疾病

  • 潛在市場
  • 競爭情形

市場企業的簡介

目錄
Product Code: JPT456K

Immune-mediated inflammatory diseases (IMIDs) is a term that encompasses a number of common, chronic and complex disorders, characterized by a dysregulation of the normal immune response which leads to inflammation in target organs and, usually, systemic effects as well. Examples include type 1 diabetes (T1D), Crohn's disease (CD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS) and psoriasis. This report examines the therapeutic products and strategies that are being employed to improve outcomes by modulating the intracellular production of inflammatory mediators.

What You Will Learn

  • What are the immune factors in the Th17 helper cell pathway that are responsible for immune mediated inflammatory Autoimmune Diseases?
  • What are the inflammatory-mediated ligands, receptors, signaling proteins and transcription factors that represent druggable targets in the Th17 helper cell?
  • What are the major factors driving the high level of development activity in immune mediated inflammatory diseases?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2022?
  • What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics

Executive Summary

The Th17 Pathway

Th17 Inflammatory Pathway Cascade Targets

Interleukin 6 (IL-6)

  • Approved Drugs
  • Development-stage Drugs

Interleukin IL-6R

  • Approved Drugs
  • Development-stage Drugs

Janus Kinase/Tyrosine Kinase Inhibitors

  • Approved Drugs
  • Development-stage Drugs

Signaling Proteins

  • Signal Transducer and Activator of Transcription (STAT)

Interleukin-21 (IL-21)

Interleukin-21R (IL-21R)

Interleukin-23 (IL-23)

  • Approved Drugs
  • Development-stage Drugs

Interleukin-23R (IL-23R)

Interleukin-17A (IL-17A)

  • Approved Drugs

Interleukin-17C (IL-17C)

  • Development-stage Drugs

Interleukin 17A/17F

  • Development-stage Drugs

Interleukin-17RA (IL-17RA)

  • Approved Drugs

Transforming Growth Factor-β RI/RII (TGF-β RI/RII)

  • Development-stage Drugs

Retinoic acid-related orphan receptor (RORyt)

  • Development-stage Drugs

Interleukin 17

  • Development-stage Drugs

Interleukin-22 (IL-22)

Market Status

Market Size

Competitive Landscape

Th17 Pathway Mediated Inflammatory Diseases

  • Addressable Market
  • Competitive Landscape

Profiles of Market Participants

Back to Top